Compare Bank of New York Mellon Corp (BNY) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs ClearPoint Neuro Inc — how do they compare? Bank of New York Mellon Corp trades at $162.85 (market cap $108.78B), while ClearPoint Neuro Inc trades at $14.55 (market cap $454.21M). The key difference: Bank of New York Mellon Corp is far larger — about 239.5× ClearPoint Neuro Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| BNY | CLPT | |
|---|---|---|
Market Cap | $108.78B | $454.21M |
Sector | Financials | Health |
52-Week High | $162.35 | $29.60 |
52-Week Low | $101.00 | $8.66 |
Dividend Yield | 1.38% | — |
Enterprise Value | — | $488.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $159.44, up 1.14% on the day, near the analyst consensus price target of $170.36. The stock shows a bullish technical trend with strong moving average signals, and fundamentals are robust with consistent earnings beats, revenue growth to $19.76B in 2025, and a net income margin of 29.96%. Recent news highlights strategic moves in digital asset infrastructure and a dividend declaration.
The outlook for BNY is positive, supported by earnings momentum and digital innovation, but risks include high investing cash outflows and interest expenses. Analyst sentiment is mixed with a slight hold bias, yet institutional upgrades and a strong ROE of 15.34% offer upside potential amid market volatility.
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
